Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The overall goal of this study is to promote awareness of Familial Hypercholesterolemia (FH). The investigators aim to enroll patients with suspected FH into the study and will randomize them to receive usual care or motivational interview. Primary study outcomes include knowledge of FH, as well as clinical and patient-reported outcomes. This study aims to promote optimal disease management and improve outcomes of FH patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 75
Healthy Volunteers: t
View:

• Age 2-75 years

• patients with existing clinical diagnosis or suspected FH

• known genetic mutation of FH

• patients with an initial (pretreatment) LDL level \>190 mg/dL or total cholesterol \>300 mg/dL (age \>19 years) or LDL-c \> 160mg/dL or total cholesterol \>260 mg/dL in children age 2-19 years

• patients currently taking a lipid-lowering medication and have an LDL \>124 mg/dL or total cholesterol \>195 mg/dL

• capable of providing informed consent

• Patients should reside in Minnesota, Wisconsin or North Dakota.

Locations
United States
Minnesota
Aspirus St. Luke's Hospital
RECRUITING
Duluth
Essentia Health
RECRUITING
Duluth
Contact Information
Primary
Catherine Benziger, MD MPH
cholesterolstudy@essentiahealth.org
218-576-0506
Time Frame
Start Date: 2022-02-15
Estimated Completion Date: 2025-12
Participants
Target number of participants: 300
Treatments
Experimental: Motivational Interview
Motivational interview arm will receive a message to schedule a follow up motivational interview via telephone or video after the baseline survey as well as follow up surveys.
No_intervention: Usual Care
Usual care arm will receive baseline and follow up surveys only.
Sponsors
Collaborators: Aspirus St. Luke's Hospital, WHITESIDE Institute for Clinical Research
Leads: Essentia Health

This content was sourced from clinicaltrials.gov